Dr Reddy's launches insomnia drug in US; Glenmark gets FDA nod

Pharma major Dr Reddy's Laboratories today said it has launched a drug to treat insomnia in the US market, following approval by the Food & Drug Administration (FDA).

The company has started selling 1 mg, 2 mg and 3 mg tablets of Eszopiclone, a generic version of Lunesta, a sedative drug that is used for the treatment of insomnia.

Sunovion Pharmaceuticals Inc is the owner of the Eszopiclone drug.

According to IMS Health, Lunesta tablets and generics combined had US sales of about $887 million for the 12 months ended January 2014, Dr Reddy's said in a filing with the stock exchanges.

Dr Reddy's said 1 mg tablets are available in bottle counts of 30, while 2 mg and 3 mg tablets will be sold in bottle counts of 100.

Dr Reddy's shares traded at Rs 2,542.95 on the BSE in afternoon trade, down 1.54 per cent.

Glenmark Generics Inc, a subsidiary of Glenmark Generics Ltd, said in a separate statement that it has been granted final abbreviated new drug approval from the FDA for Eszopiclone tablets.

"Glenmark will commence distribution of the product immediately. The approval is for the 1 mg, 2 mg and 3 mg tablets," Glenmark said in the statement.

Glenmark shares quoted at Rs 582.40 on the BSE, up 0.18 per cent.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • But what’s the big deal about Modi’s first hundred days?

    That Indians believe more in symbolism than substance is a fact that is well acknowledged and chronicled.

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Urs Schöttli

West Asia turmoil worries east Asia

From Beijing to Jakarta, from Manila to Tokyo, east Asian ...

Purnendu Ghosh

Memory is a collage of the old and new

We are all fitted with pressure valves. Some of us ...

Shona Adhikari

The enduring legacy of <em>The Last Supper</em>

This week’s column features a work of art that is ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture